Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Section 3 of 6

Product information and disease description

391 evidence topics · 218 sources

Product description

Phase of product development

Executive Order 14401 on timely rescheduling and priority vouchers for psychedelic drugs

Product information

Generic, brand name and therapeutic class of product
Dosage forms and strengths
Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
Indication
Pharmacology
Mechanism of action
Psilocybin as a prodrug of psilocin, a partial agonist at serotonin receptors
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Participants aged 65 years and older in the phase 3 trials
Trial and armAge, years, minimum and maximumAge 65 years or older, n (%)
COMP005, COMP360 25 mg (N=171)“19, 77”“15 (8.8)”
COMP005, placebo (N=87)“22, 72”“11 (12.6)”
COMP006, COMP360 25 mg (N=296)“18, 79”“29 (9.8)”
COMP006, COMP360 10 mg (N=142)“19, 73”“9 (6.3)”
COMP006, COMP360 1 mg (N=143)“20, 75”“13 (9.1)”
Drug/Drug, drug/disease interactions
Effects of other drugs on Psilocybin
Effects of Psilocybin on other drugs
Dosing and administration
Dosage
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Adjunctive SSRI: COMP360 25 mg with an ongoing SSRI
Effect of Psilocybin on quality measures
Product comparison
Usona Institute psilocybin in major depressive disorder

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of Treatment-resistant depression
United States commercial, Medicaid, and Medicare claims: incidence by operating definition
DatabaseCap on time for a regimen to failNumber of casesIncidence estimateIncidence 95% CI
CCAE3 months“4,791”View highlighted excerpt for this quote“33.93”View highlighted excerpt for this quote“32.97, 34.89”View highlighted excerpt for this quote
MDCD3 months“661”View highlighted excerpt for this quote“65.71”View highlighted excerpt for this quote“60.71, 70.72”View highlighted excerpt for this quote
MDCR3 months“228”View highlighted excerpt for this quote“13.08”View highlighted excerpt for this quote“11.39, 14.78”View highlighted excerpt for this quote
CCAE6 months“7,130”View highlighted excerpt for this quote“50.49”View highlighted excerpt for this quote“49.33, 51.65”View highlighted excerpt for this quote
MDCD6 months“987”View highlighted excerpt for this quote“98.12”View highlighted excerpt for this quote“92.01, 104.24”View highlighted excerpt for this quote
MDCR6 months“320”View highlighted excerpt for this quote“18.36”View highlighted excerpt for this quote“16.36, 20.37”View highlighted excerpt for this quote
CCAE24 months“9,038”View highlighted excerpt for this quote“64.00”View highlighted excerpt for this quote“62.69, 65.32”View highlighted excerpt for this quote
MDCD24 months“1,209”View highlighted excerpt for this quote“120.20”View highlighted excerpt for this quote“113.43, 126.96”View highlighted excerpt for this quote
MDCR24 months“404”View highlighted excerpt for this quote“23.19”View highlighted excerpt for this quote“20.93, 25.45”View highlighted excerpt for this quote

“Incidence/100,000 cohort members/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Truven MarketScan Commercial Claims and Encounters (CCAE), with approximately 35 million mainly privately insured subscribers in 2011; Truven MarketScan Medicaid (MDCD), a means-tested public insurance program with approximately 5 million subscribers in 2011, and Truven MarketScan Medicare Supplemental Beneficiaries (MCDR), a public insurance program that is not means-tested, with approximately 3 million subscribers in 2011, most of whom were aged 65 or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“we defined TRD as failure of two medications as evidenced by their replacement or supplementation by other medications, and set maximum durations (caps) for how long a medication regimen could remain in use and still be eligible to fail.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“TRD incidence estimates varied approximately 2-fold between the two databases (CCAE, Medicaid) that described socioeconomically different non-elderly populations; for a given cap varied 2-fold to 4-fold within each database across the other implementation choices; and if the cap was also allowed to vary, varied 6-fold or 7-fold within each database.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“among such studies the proportion of PTD cases that develop into TRD cases ranges from 35% in a study limited to PTD subjects with a diagnosis of MDD [9] to less than 10% in a study that included a wider range of depression diagnoses among the PTD subjects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Prevalence of Treatment-resistant depression
Natural history, survival, and mortality
Pathophysiology
Diagnosis
Confirming treatment resistance: excluding pseudo-resistance

“Reviewed herein are the most common modifiable contributors to pseudo‐resistance, including inaccuracy of the MDD diagnosis, inadequacy of current and past treatment trials, inaccurate assessment of response, and individual differences in the metabolism of antidepressants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Inaccuracy of the MDD diagnosis is a common reason for pseudo‐resistance. It is estimated that approximately half of individuals with MDD are not correctly diagnosed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Furthermore, it is reported that the transition from a diagnosis of MDD to one of bipolar disorder occurs at a rate of approximately 1‐3% per year, indicating that diagnostic assessment must be reconsidered in all TRD presentations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The adequate duration of an antidepressant trial is generally considered to be 4‐6 weeks at optimal dosing, although 60% of persons who achieved remission in the STAR*D trial with level 1 treatment did so after week 6 of treatment, indicating that a subpopulation of adults with MDD may require longer treatment trials” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Using this definition, about 30‐50% of persons prescribed with antidepressants are non‐adherent in acute phase treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although pharmacogenetic testing cannot be recommended as a routine assessment in TRD, some preliminary evidence does suggest that, in select circumstances, it may be warranted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Staging models: Maudsley Staging Method
Rating scales: response, nonresponse, and remission thresholds
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Treatment-resistant depression
Humanistic burden and health-related quality of life
Quality of life, functioning, and work productivity in TRD versus non-TRD MDD: Sequenced Treatment Alternatives to Relieve Depression trial secondary analysis
Economic burden and healthcare resource utilization
Economic impact of Treatment-resistant depression on families
Economic impact of diagnostic testing

Not applicable.

Approaches to treatment

Current treatment options and standard of care
Antidepressant optimization, switching, and combination
CANMAT guideline: dose optimization, switching, and sequencing of adjunctive strategies

“Optimizing the antidepressant dose is an important first step.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Higher than minimal therapeutic doses are more effective (to a plateau around the equivalent of 50 mg of fluoxetine) but less well-tolerated” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The evidence for the efficacy of switching antidepressants is inconsistent. Meta-analyses show that switching to another antidepressant is not superior to continuing the same one and there appears to be diminishing response rates for antidepressant monotherapy beyond the first switch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Moreover, RCTs directly comparing switching to adjunctive strategies have shown that adjunctive strategies have superior outcomes and often similar tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Hence, while balancing individual risks, benefits, and patient preference, CANMAT recommends that adjunctive strategies be considered earlier in the treatment algorithm, after limited response to the first or second antidepressant trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Switching should be considered first when there is no response to the initial antidepressant or when the first medication has troublesome side effects. Adjunctive strategies should be considered first when there is a partial response to the initial antidepressant and there are minimal or no tolerability issues with the first medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

VA/DoD guideline: evidence on dose escalation, switching, and antidepressant combinations
Switching after SSRI failure: remission and response with bupropion, sertraline, or venlafaxine
Second-generation antipsychotic augmentation
Aripiprazole label: change in MADRS total score at week 6
StudyPlacebo-subtracted difference in MADRS change (95% CI)
Study 1“-2.84 (-4.53, -1.15)”
Study 2“-3.01 (-4.66, -1.37)”
Brexpiprazole label: change in MADRS total score at week 6
Study and dosePlacebo-subtracted difference in MADRS change (95% CI)
Study 1, 2 mg/day“-3.2 (-4.9, -1.5)”
Study 2, 1 mg/day“-1.3 (-2.7, 0.1)”
Study 2, 3 mg/day“-2.0 (-3.4, -0.5)”
Lithium and thyroid hormone augmentation
Psychotherapy
Esketamine and ketamine
Repetitive transcranial magnetic stimulation
CANMAT guideline: rTMS and theta burst protocols

“Repetitive TMS shows efficacy for DTD, with response rates of 40% to 50%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“High-frequency (5 Hz or higher) rTMS delivered over the left dorsolateral prefrontal cortex (DLPFC) has the largest evidence base and is recommended as a first-line protocol, along with low-frequency (1 Hz or lower) rTMS delivered over the right DLPFC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“TBS is recommended as a first-line protocol” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Accelerated iTBS to the left DLPFC has evidence for efficacy and a large RCT found no significant differences between accelerated bilateral TBS and high frequency rTMS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Unlike ECT, rTMS does not require anaesthesia and has no cognitive side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Finally, except in emergent situations as mentioned above, rTMS should generally be considered before ECT, given its less invasive nature and that individuals may continue to work or attend school while undergoing rTMS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Electroconvulsive therapy
CANMAT guideline: efficacy, course, and cognitive effects of ECT

“ECT remains one of the most effective treatment options for patients with TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“ECT has demonstrated evidence of efficacy and tolerability in the treatment of depressive episodes, with response rates ranging from 65% to 75%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“An acute course of ECT usually requires 6 to 12 sessions, with no difference in response outcomes between sessions given twice or thrice weekly” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Adverse effects on cognition are of most concern, although modern ECT techniques, including unilateral electrode placement and refined electrical dosing, have reduced both the incidence and severity of cognitive side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Nevertheless, some patients report significant and distressing gaps in autobiographical memory long after ECT, and the discrepancy between cognitive performance and subjective memory dysfunction remains controversial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although ECT has high response rates during acute treatment, recurrence occurs in 60% to 80% of patients at 6-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Vagus nerve stimulation and other neuromodulation
Limitations of current therapies
Summary

In the Sequenced Treatment Alternatives to Relieve Depression trial, remission rates fell from 36.8% at step 1 to 13.0% at step 4, with higher relapse rates after more steps, and a reanalysis with the protocol-stipulated HRSD found a cumulative remission rate of 35.0% against the reported 67%. ICER's draft scope states that another antidepressant course succeeds much less often in TRD. Adjunctive atypical antipsychotics have a “greater side effect burden than antidepressant monotherapy”: one analysis reported akathisia with aripiprazole (NNH 4) and sedation with quetiapine (NNH 3), and one study found higher all-cause mortality with antipsychotic use (HR 1.21). Esketamine is dispensed and administered only in certified healthcare settings, with monitoring for at least 2 hours at each session, and ketamine and esketamine often require repeated visits for maintenance doses and have limited access in some regions. In one analysis, ketamine effects lasted no more than one week. After successful ECT, 51.1% of patients relapsed by 12 months on continuation pharmacotherapy, and ECT use is limited by stigma, general anaesthesia, and concern about cognitive effects. rTMS requires daily clinic visits, psychotherapy can be burdensome because of frequent visits, and access is limited because not all providers have adequate training, and VNS carries a greater than 5% chance of significant adverse events.

Place in treatment, anticipated use, and care setting
Summary

COMPASS has submitted a New Drug Application for COMP360 for TRD, which its press release defines as an inadequate response to two or more courses of antidepressants of adequate dose and duration. Guidelines that address psilocybin restrict it to research: the VA/DoD guideline recommends against psilocybin for MDD “outside of a research setting”, with very low confidence in the evidence; the CANMAT guideline update considers psilocybin-assisted psychotherapies “investigational treatments”; and a CANMAT task force recommends use primarily within clinical trials. The EMA guideline recommends starting psychedelic development in TRD and states that psychedelics need administration “in a controlled environment”. ICER's draft scope assesses psilocybin 25 mg in adults with MDD without psychotic features after two or more failed adequate antidepressant trials in the current episode, with esketamine, intravenous ketamine, and rTMS as comparators focusing on US outpatient settings. The company's November 2026 investor presentation states that dosing and monitoring will take place at a certified treatment center, and its quarterly release cites more than 8,500 treatment centers. The company described one or two initial administrations followed by episodic dosing per physician decision. Payer panel participants named head-to-head trials against esketamine or other active comparators as the most important evidence for coverage.

Anticipated care setting: certified interventional psychiatry treatment centers
Heterogeneity of treatment effect
Care management intervention strategies
Three-phase psychological support model used in COMP360 trials
Payer coverage criteria and reauthorization proposed for psilocybin

“All payer participants agreed that coverage criteria would align with the FDA-approved product label including, for instance, the quantity and frequency of treatment, and would comply with the REMS requirements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Several added they would look to previous experience with esketamine for guidance and that coverage criteria for psilocybin may be similar.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Whereas some participants would accept provider attestation for continuation of therapy, others would require documentation of improvement and sustained treatment response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“One PBM participant suggested that reviewing claims for other TRD treatments subsequent to psilocybin administration could further support determination of treatment response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants discussed reimbursement considerations with coverage of psilocybin including developing a bundled payment model combining all related services (eg, medication, administration, psychotherapy) into a single billable episode of care” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Expected outcomes with further conventional treatment steps or usual care